Avalo Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Avalo Therapeutics
AVTX Stock  USD 18.16  0.35  1.97%   
Avalo Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Avalo Therapeutics' valuation are provided below:
Gross Profit
-31.9 M
Market Capitalization
329.3 M
Enterprise Value Revenue
1.1 K
Revenue
192 K
Earnings Share
(13.42)
We have found one hundred twenty available fundamental signals for Avalo Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Avalo Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 71 M in 2026, despite the fact that Enterprise Value is likely to grow to (77.8 M).

Avalo Therapeutics Total Revenue

377,055

Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 184.6 K, Selling General Administrative of 11.8 M or Total Revenue of 377.1 K, as well as many indicators such as Price To Sales Ratio of 150, Dividend Yield of 0.0 or PTB Ratio of 0.43. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Avalo Stock
Check out the analysis of Avalo Therapeutics Correlation against competitors.
For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Avalo Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets182 M173.3 M53.5 M
Slightly volatile
Other Current Liabilities8.3 M7 M6.7 M
Slightly volatile
Total Current Liabilities11.7 M8 M9.5 M
Slightly volatile
Property Plant And Equipment Net1 M1.4 M867.2 K
Slightly volatile
Accounts Payable309.2 K325.4 K1.3 M
Very volatile
Cash162.5 M154.7 M37.2 M
Slightly volatile
Non Current Assets Total15 M13.6 M12.1 M
Slightly volatile
Other Assets0.860.91.9 M
Very volatile
Cash And Short Term Investments162.5 M154.7 M37.7 M
Slightly volatile
Common Stock Shares Outstanding13 M12.4 M2.2 M
Slightly volatile
Other Current Assets2.5 M4.3 M2.2 M
Slightly volatile
Other Stockholder Equity607.7 M578.8 M195.3 M
Slightly volatile
Total Liabilities26.1 M20.4 M21.1 M
Slightly volatile
Total Current Assets167.7 M159.7 M41.4 M
Slightly volatile
Common Stock8.6 K9 K174.5 K
Very volatile
Liabilities And Stockholders Equity182 M173.3 M52.6 M
Slightly volatile
Non Current Liabilities Total11.8 M9.7 M15.1 M
Pretty Stable
Short and Long Term Debt Total620.5 K653.2 K7.7 M
Very volatile
Short Term Debt485.6 K511.2 K1.6 M
Pretty Stable
Net Receivables522.4 K549.9 K1.7 M
Pretty Stable
Other Liabilities5.8 M6.3 M5.7 M
Pretty Stable
Good Will10.9 M9.5 M13.5 M
Slightly volatile
Common Stock Total Equity64.1 K67.5 K1.3 M
Slightly volatile
Net Invested Capital160.6 M153 M48.4 M
Slightly volatile
Property Plant And Equipment Gross1.9 M2.2 M1.1 M
Slightly volatile
Non Current Liabilities Other3.1 M2.1 M3.7 M
Pretty Stable
Intangible Assets32.5 K34.2 K10.4 M
Slightly volatile
Property Plant Equipment1.6 M2.8 M1.1 M
Slightly volatile
Long Term Debt16.2 M12.1 M17.4 M
Pretty Stable
Short and Long Term Debt3.8 M6.8 M3.3 M
Slightly volatile
Capital Stock8.6 K9 K39.2 K
Slightly volatile
Capital Surpluse161.8 M182 M198.7 M
Slightly volatile
Capital Lease Obligations560.6 K653.2 K472.1 K
Slightly volatile
Deferred Long Term Liabilities72.3 K81.4 K88.8 K
Slightly volatile
Preferred Stock Total Equity1 K1.1 K1.2 K
Slightly volatile

Avalo Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization184.6 K194.3 K628 K
Pretty Stable
Selling General Administrative11.8 M18.9 M10.2 M
Slightly volatile
Total Revenue377.1 K396.9 K5.4 M
Pretty Stable
Other Operating Expenses83.3 M79.3 M33.8 M
Slightly volatile
Research Development62.9 M59.9 M23.4 M
Slightly volatile
Total Operating Expenses83.7 M79.7 M31.5 M
Slightly volatile
Interest Expense5.4 M3.8 M4 M
Slightly volatile
Selling And Marketing Expenses674.6 K710.1 K1.4 M
Very volatile
Reconciled Depreciation144.5 K152.1 K948.5 K
Very volatile
Interest Income68.1 K44 K92.3 K
Slightly volatile
Non Recurring20.4 M23 M25.1 M
Slightly volatile
Non Operating Income Net Other4.5 M5.1 M5.5 M
Slightly volatile

Avalo Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.6 M6.7 M3.2 M
Slightly volatile
Begin Period Cash Flow13.9 M8.7 M11.1 M
Slightly volatile
Depreciation184.6 K194.3 K787.1 K
Pretty Stable
End Period Cash Flow162.6 M154.9 M37.3 M
Slightly volatile
Dividends Paid13.4 M17 M8.5 M
Slightly volatile
Issuance Of Capital Stock139.6 M133 M35.2 M
Slightly volatile
Cash And Cash Equivalents Changes12.3 M13.8 M15.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1501572.1 K
Slightly volatile
Days Sales Outstanding478455162
Slightly volatile
Average Payables1 M1.6 M1.4 M
Slightly volatile
Stock Based Compensation To Revenue12.5411.944.1324
Slightly volatile
Capex To Depreciation0.610.660.5944
Slightly volatile
Inventory Turnover12415585.0369
Slightly volatile
Days Of Inventory On Hand2.322.4417.7538
Very volatile
Sales General And Administrative To Revenue35.2533.5813.0717
Pretty Stable
Average Inventory377.2 K671.8 K461.6 K
Slightly volatile
Research And Ddevelopement To Revenue11210641.4976
Very volatile
Capex To Revenue0.09920.09440.0609
Pretty Stable
Cash Per Share18.0819.042 K
Pretty Stable
Income Quality0.71.260.89
Pretty Stable
Intangibles To Total Assets0.07610.08010.5163
Slightly volatile
Current Ratio18.8617.965.62
Slightly volatile
Receivables Turnover0.790.836.0876
Slightly volatile
Capex Per Share0.620.656.5938
Very volatile
Average Receivables2.4 M4.1 M3 M
Slightly volatile
Revenue Per Share0.05930.0624506
Very volatile
Interest Debt Per Share0.390.41778
Pretty Stable
Debt To Assets0.02110.02230.3033
Slightly volatile
Graham Number10.8 K12.1 K13.3 K
Slightly volatile
Operating Cycle478455165
Slightly volatile
Ebt Per Ebit0.870.461.0286
Very volatile
Quick Ratio18.8617.965.6151
Slightly volatile
Net Income Per E B T0.780.90.9129
Slightly volatile
Cash Ratio18.2717.45.2284
Slightly volatile
Days Of Inventory Outstanding2.322.4417.7538
Very volatile
Days Of Sales Outstanding478455162
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.90.9966
Slightly volatile
Fixed Asset Turnover0.40.4246.2828
Very volatile
Debt Ratio0.02110.02230.3033
Slightly volatile
Price Sales Ratio1501572.1 K
Slightly volatile
Asset Turnover0.00320.00340.1635
Very volatile

Avalo Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap71 M54.4 M59.4 M
Slightly volatile

Avalo Fundamental Market Drivers

Avalo Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Avalo Therapeutics Financial Statements

Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue101.2 K96.1 K
Total Revenue396.9 K377.1 K
Cost Of Revenue-329.4 K-312.9 K
Stock Based Compensation To Revenue 11.94  12.54 
Sales General And Administrative To Revenue 33.58  35.25 
Research And Ddevelopement To Revenue 106.28  111.60 
Capex To Revenue 0.09  0.10 
Revenue Per Share 0.06  0.06 
Ebit Per Revenue(178.66)(169.73)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY